We are delighted to announce that we have completed the first clinical trial of patientMpower for kidney dialysis. The study (NCT03403491), which was conducted in conjunction with Professor Conall O’Seaghdha and his team at Beaumont Hospital in Dublin, compared the use of patientMpower to usual care in patients undergoing kidney dialysis.
Learn what our digital therapeutic will use
This trial is the first step in patientMpower’s plan to develop a digital therapeutic to enable physicians to prescribe self-care for their kidney dialysis patients. Patients having dialysis need to follow a demanding program of dialysis sessions, fluid and diet restrictions, as well as taking multiple medications in order to avoid complications. Our digital therapeutic uses integrated monitoring, proprietary algorithms and behaviour modifications tools to empower self-care, improving patient outcomes and reducing the burden on healthcare services.
Hear from Dr. Colin Edwards, CSO at patientMpower
Dr. Colin Edwards, Chief Scientific Officer at patientMpower said, “This clinical trial looked at the effect of patientMpower compared to usual care on a variety of measures including fluid management, blood pressure control and the need for additional dialysis sessions. The initial feedback from the patients enrolled in this pilot study has been overwhelmingly positive. Patients are finding patientMpower really useful in managing all of the things they need to control and monitor. We are now in the process of analysing the trial data and examining the impact of patientMpower on clinical outcomes, and will be in a position to present that data at congresses later this year.”
What do kidney dialysis patients need while on dialysis?
“Development work on the kidney dialysis digital therapeutic is now at full pace” said Eamonn Costello, CEO at patientMpower. “Kidney dialysis patients really need proven interventions to help them take control of their life on dialysis. Not only does better self-care lower the risk of complications for patients, but it also reduces missed dialysis sessions and unplanned hospitalisations which currently cost dialysis providers and healthcare systems billions of dollars every year.” Larger scale clinical trials in kidney dialysis, including a study conducted with the Rogosin Institute in New York, are due to initiate very shortly. “We are on track to deliver the first digital therapeutic for kidney dialysis patients by the end of 2020.” said Eamonn.
by Jennifer Bulandr
